"nephrology" MCQ (SBA): KDIGO Guideline (2024): Evaluation and Management of CKD

Instant feedback + full explanation. One question, done properly.

Hard"KDIGO risk stratification uses both GFR and albuminuria categories to guide prognosis and management. Biopsy or MRI are not routinely indicated; ACEI should be continued unless contraindicated; cystatin C may be used to confirm eGFR in select casesKDIGO Guideline (2024): Evaluation and Management of CKD"nephrology"

A 73-year-old woman with stage 3b CKD (eGFR 39) has UACR 35 mg/g. BP 138/76 on ACE inhibitor. According to KDIGO 2024, which additional evaluation is standard for risk stratification?

Practice more on iatroX

Educational content. Not a substitute for clinical judgement or local policy.

"nephrology" MCQ: KDIGO Guideline (2024): Evaluation and Management of